Omada Health drew strong retail attention after Morgan Stanley, Evercore ISI, and Barclays raised price targets to $28-$32 following its beat and raise Q3 results. The company posted its first positive adjusted EBITDA and plans to add GLP-1 prescribing to its weight-health platform. Traders cited Omada strong balance sheet and high margins as key growth drivers.